All Pharma News
bluebird bio Announces Receipt of Expected Notice from Nasdaq

bluebird bio Announces Receipt of Expected Notice from Nasdaq
BUSINESSWIRE
26 Apr 2024
Share Share
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BUSINESSWIRE
11 Apr 2024
Share Share
bluebird bio Reports Fourth Quarter and 2023 Annual Results

bluebird bio Reports Fourth Quarter and 2023 Annual Results
BUSINESSWIRE
26 Mar 2024
Share Share
Bluebird discusses Lyfgenia launch details and accounting errors

Bluebird discusses Lyfgenia launch details and accounting errors
Kevin Dunleavy FIERCE PHARMA
26 Mar 2024
Share Share
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital

bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
BUSINESSWIRE
18 Mar 2024
Share Share
Bluebird secures $175M loan from Hercules Capital

Bluebird secures $175M loan from Hercules Capital
Zoey Becker FIERCE PHARMA
18 Mar 2024
Share Share
bluebird bio Announces First Outcomes-Based Agreement with Medicaid

bluebird bio Announces First Outcomes-Based Agreement with Medicaid
BUSINESSWIRE
11 Mar 2024
Share Share
Michigan Medicaid signs deal with bluebird for SCD gene therapy

Michigan Medicaid signs deal with bluebird for SCD gene therapy
Kevin Dunleavy FIERCE PHARMA
11 Mar 2024
Share Share
JPM24: Bluebird CEO defends Lyfgenia pricing premium, EU retreat

JPM24: Bluebird CEO defends Lyfgenia pricing premium, EU retreat
FIERCE PHARMA
10 Jan 2024
Share Share
Bluebird is looking for financing as it brings sickle cell therapy to market

Bluebird is looking for financing as it brings sickle cell therapy to market
Drew Armstrong ENDPTS
10 Jan 2024
Share Share